Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 12 May 1989:
Vol. 244. no. 4905, pp. 707 - 712
DOI: 10.1126/science.2470152
Prev | Table of Contents | Next

Articles

Science, Vol 244, Issue 4905, 707-712
Copyright © 1989 by American Association for the Advancement of Science

articles

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

DJ Slamon, W Godolphin, LA Jones, JA Holt, SG Wong, DE Keith, WJ Levin, SG Stuart, J Udove, A Ullrich, and al. et

Department of Medicine, U.C.L.A. School of Medicine 90024.

Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/neu in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/neu in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion.
T.-H. Huang, F. Wu, G. B. Loeb, R. Hsu, A. Heidersbach, A. Brincat, D. Horiuchi, R. J. Lebbink, Y.-Y. Mo, A. Goga, et al. (2009)
J. Biol. Chem. 284, 18515-18524
   Abstract »    Full Text »    PDF »
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial.
M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja, U. Dafni, J. Rueschoff, B. Jordan, S. Dolci, M. Abramovitz, O. Stoss, et al. (2009)
J. Clin. Oncol. 27, 2962-2969
   Abstract »    Full Text »    PDF »
Molecular Subtypes of Breast Cancer Emerging in Young Women in Taiwan: Evidence for More Than Just Westernization as a Reason for the Disease in Asia.
C.-H. Lin, J.-Y. Liau, Y.-S. Lu, C.-S. Huang, W.-C. Lee, K.-T. Kuo, Y.-C. Shen, S.-H. Kuo, C. Lan, J. M. Liu, et al. (2009)
Cancer Epidemiol. Biomarkers Prev. 18, 1807-1814
   Abstract »    Full Text »    PDF »
HER-2/neu analysis in breast cancer bone metastases.
J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al. (2009)
J. Clin. Pathol. 62, 542-546
   Abstract »    Full Text »    PDF »
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging.
E. C.F. Dijkers, J. G.W. Kosterink, A. P. Rademaker, L. R. Perk, G. A.M.S. van Dongen, J. Bart, J. R. de Jong, E. G.E. de Vries, and M. N. Lub-de Hooge (2009)
J. Nucl. Med. 50, 974-981
   Abstract »    Full Text »    PDF »
Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme.
Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII (2009)
Anticancer Res 29, 2137-2146
   Abstract »    Full Text »    PDF »
Common Polymorphism in the Phosphatase PHLPP2 Results in Reduced Regulation of Akt and Protein Kinase C.
J. Brognard, M. Niederst, G. Reyes, N. Warfel, and A. C. Newton (2009)
J. Biol. Chem. 284, 15215-15223
   Abstract »    Full Text »    PDF »
Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers.
D. J. Slamon and M. F. Press (2009)
J Natl Cancer Inst 101, 615-618
   Full Text »    PDF »
Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas.
K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang (2009)
Cancer Res. 69, 4036-4042
   Abstract »    Full Text »    PDF »
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma.
K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al. (2009)
Am. J. Pathol. 174, 1597-1601
   Abstract »    Full Text »    PDF »
14-3-3{zeta} Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival.
C. L. Neal, J. Yao, W. Yang, X. Zhou, N. T. Nguyen, J. Lu, C. G. Danes, H. Guo, K.-H. Lan, J. Ensor, et al. (2009)
Cancer Res. 69, 3425-3432
   Abstract »    Full Text »    PDF »
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al. (2009)
Clin. Cancer Res. 15, 2895-2904
   Abstract »    Full Text »    PDF »
Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations.
Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige (2009)
Am J Clin Pathol 131, 490-497
   Abstract »    Full Text »    PDF »
ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells.
V. S. Hawthorne, W.-C. Huang, C. L. Neal, L.-M. Tseng, M.-C. Hung, and D. Yu (2009)
Mol. Cancer Res. 7, 592-600
   Abstract »    Full Text »    PDF »
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas.
D. S.P. Tan, M. B.K. Lambros, S. Rayter, R. Natrajan, R. Vatcheva, Q. Gao, C. Marchio, F. C. Geyer, K. Savage, S. Parry, et al. (2009)
Clin. Cancer Res. 15, 2269-2280
   Abstract »    Full Text »    PDF »
HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil.
H. Korkaya and M. S. Wicha (2009)
Clin. Cancer Res. 15, 1845-1847
   Abstract »    Full Text »    PDF »
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations.
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press (2009)
J. Clin. Oncol. 27, 1323-1333
   Abstract »    Full Text »    PDF »
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis.
T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela (2009)
PNAS 106, 3294-3299
   Abstract »    Full Text »    PDF »
Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth.
C. J. Proietti, C. Rosemblit, W. Beguelin, M. A. Rivas, M. C. Diaz Flaque, E. H. Charreau, R. Schillaci, and P. V. Elizalde (2009)
Mol. Cell. Biol. 29, 1249-1265
   Abstract »    Full Text »    PDF »
Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9.
L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al. (2009)
Clin. Cancer Res. 15, 1575-1584
   Abstract »    Full Text »    PDF »
Targeted Cancer Therapeutics.
W. N. Hait and T. W. Hambley (2009)
Cancer Res. 69, 1263-1267
   Abstract »    Full Text »    PDF »
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas.
D. Etemadmoghadam, A. deFazio, R. Beroukhim, C. Mermel, J. George, G. Getz, R. Tothill, A. Okamoto, M. B. Raeder, AOCS Study Group, et al. (2009)
Clin. Cancer Res. 15, 1417-1427
   Abstract »    Full Text »    PDF »
Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer.
J. HORIGUCHI, T. OYAMA, Y. KOIBUCHI, T. YOKOE, D. TAKATA, F. IKEDA, H. NAGAOKA, N. ROKUTANDA, R. NAGAOKA, Y. ISHIKAWA, et al. (2009)
Anticancer Res 29, 517-524
   Abstract »    Full Text »    PDF »
Genetically Targeted T Cells Eradicate Established Breast Cancer in Syngeneic Mice.
H. Wang, H. Wei, R. Zhang, S. Hou, B. Li, W. Qian, D. Zhang, G. Kou, J. Dai, and Y. Guo (2009)
Clin. Cancer Res. 15, 943-950
   Abstract »    Full Text »    PDF »
Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways.
L. I. Gordon, M. A. Burke, A. T. K. Singh, S. Prachand, E. D. Lieberman, L. Sun, T. J. Naik, S. V. N. Prasad, and H. Ardehali (2009)
J. Biol. Chem. 284, 2080-2087
   Abstract »    Full Text »    PDF »
Thyroid Hormone Receptor {beta}1 Acts as a Potent Suppressor of Tumor Invasiveness and Metastasis.
O. Martinez-Iglesias, S. Garcia-Silva, S. P. Tenbaum, J. Regadera, F. Larcher, J. M. Paramio, B. Vennstrom, and A. Aranda (2009)
Cancer Res. 69, 501-509
   Abstract »    Full Text »    PDF »
A Systems Approach to Analysis of Molecular Complexity in Breast Cancer.
B. T. Hennessy, A. M. Gonzalez-Angulo, M. S. Carey, and G. B. Mills (2009)
Clin. Cancer Res. 15, 417-419
   Abstract »    Full Text »    PDF »
Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort.
S. Sieri, V. Krogh, G. Bolelli, C. A. Abagnato, S. Grioni, V. Pala, A. Evangelista, C. Allemani, A. Micheli, G. Tagliabue, et al. (2009)
Cancer Epidemiol. Biomarkers Prev. 18, 169-176
   Abstract »    Full Text »    PDF »
Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice.
O. Radkevich-Brown, J. Jacob, M. Kershaw, and W.-Z. Wei (2009)
Cancer Res. 69, 212-218
   Abstract »    Full Text »    PDF »
Breast lumps and cancer.
R. Linforth (2009)
InnovAiT 2, 17-23
   Abstract »    Full Text »    PDF »
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study.
J. Cortes, S. Di Cosimo, M. A. Climent, H. Cortes-Funes, A. Lluch, P. Gascon, J. I. Mayordomo, M. Gil, M. Benavides, L. Cirera, et al. (2009)
Clin. Cancer Res. 15, 307-314
   Abstract »    Full Text »    PDF »
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations.
M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano (2009)
Oncologist 14, 1-11
   Abstract »    Full Text »    PDF »
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers.
S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon (2008)
J. Clin. Oncol. 26, 5697-5704
   Abstract »    Full Text »    PDF »
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer.
A. Di Leo, H. L. Gomez, Z. Aziz, Z. Zvirbule, J. Bines, M. C. Arbushites, S. F. Guerrera, M. Koehler, C. Oliva, S. H. Stein, et al. (2008)
J. Clin. Oncol. 26, 5544-5552
   Abstract »    Full Text »    PDF »
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate.
G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. (2008)
Cancer Res. 68, 9280-9290
   Abstract »    Full Text »    PDF »
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
A. Kruschinski, A. Moosmann, I. Poschke, H. Norell, M. Chmielewski, B. Seliger, R. Kiessling, T. Blankenstein, H. Abken, and J. Charo (2008)
PNAS 105, 17481-17486
   Abstract »    Full Text »    PDF »
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
B. Chen, Y. Wang, S. E Kane, and S. Chen (2008)
J. Mol. Endocrinol. 41, 367-377
   Abstract »    Full Text »    PDF »
Luteinizing Hormone-Induced Up-Regulation of ErbB-2 Is Insufficient Stimulant of Growth and Invasion in Ovarian Cancer Cells.
S. W. Warrenfeltz, S. A. Lott, T. M. Palmer, J. C. Gray, and D. Puett (2008)
Mol. Cancer Res. 6, 1775-1785
   Abstract »    Full Text »    PDF »
Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists.
A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. (2008)
J. Mol. Diagn. 10, 527-536
   Abstract »    Full Text »    PDF »
DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma.
A. Sloots, C. Mastini, F. Rohrbach, R. Weth, C. Curcio, U. Burkhardt, E. Jager, G. Forni, F. Cavallo, and W. S. Wels (2008)
Clin. Cancer Res. 14, 6933-6943
   Abstract »    Full Text »    PDF »
Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer.
C.-H. Yeh, W. A. Whitmire III, and M. Albitar (2008)
Clin. Chem. 54, 1831-1839
   Abstract »    Full Text »    PDF »
PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation.
K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, K. Shoji, Y. Taketani, H. Kuramoto, Z. A. Knight, K. M. Shokat, et al. (2008)
Cancer Res. 68, 8127-8136
   Abstract »    Full Text »    PDF »
Studying copy number variations using a nanofluidic platform.
J. Qin, R. C. Jones, and R. Ramakrishnan (2008)
Nucleic Acids Res. 36, e116
   Abstract »    Full Text »    PDF »
Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non-Small-Cell Lung Cancer.
M. Barve, J. Bender, N. Senzer, C. Cunningham, F. A. Greco, D. McCune, R. Steis, H. Khong, D. Richards, J. Stephenson, et al. (2008)
J. Clin. Oncol. 26, 4418-4425
   Abstract »    Full Text »    PDF »
Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts.
C. J. Creighton, S. Massarweh, S. Huang, A. Tsimelzon, S. G. Hilsenbeck, C. K. Osborne, J. Shou, L. Malorni, and R. Schiff (2008)
Cancer Res. 68, 7493-7501
   Abstract »    Full Text »    PDF »
DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies.
P. J. Whittington, M. P. Piechocki, H. H. Heng, J. B. Jacob, R. F. Jones, J. B. Back, and W.-Z. Wei (2008)
Cancer Res. 68, 7502-7511
   Abstract »    Full Text »    PDF »
A Cautionary Note on the Evaluation of Biomarkers of Subtypes of a Single Disease.
A. J. Adewale, Q. Liu, I. Dinu, P. D. Lampe, B. L. Mitchell, and Y. Yasui (2008)
Am. J. Epidemiol. 168, 559-562
   Abstract »    Full Text »    PDF »
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
C. Gravalos and A. Jimeno (2008)
Ann. Onc. 19, 1523-1529
   Abstract »    Full Text »    PDF »
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter (2008)
Ann. Onc. 19, 1530-1539
   Abstract »    Full Text »    PDF »
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
P. Haluska, J. M. Carboni, C. TenEyck, R. M. Attar, X. Hou, C. Yu, M. Sagar, T. W. Wong, M. M. Gottardis, and C. Erlichman (2008)
Mol. Cancer Ther. 7, 2589-2598
   Abstract »    Full Text »    PDF »
Brk is coamplified with ErbB2 to promote proliferation in breast cancer.
B. Xiang, K. Chatti, H. Qiu, B. Lakshmi, A. Krasnitz, J. Hicks, M. Yu, W. T. Miller, and S. K. Muthuswamy (2008)
PNAS 105, 12463-12468
   Abstract »    Full Text »    PDF »
Chromosomal Abnormalities in Cancer.
S. Frohling and H. Dohner (2008)
N. Engl. J. Med. 359, 722-734
   Full Text »    PDF »
Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells.
M. Lombardi, G. Castoria, A. Migliaccio, M. V. Barone, R. Di Stasio, A. Ciociola, D. Bottero, H. Yamaguchi, E. Appella, and F. Auricchio (2008)
J. Cell Biol. 182, 327-340
   Abstract »    Full Text »    PDF »
Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine.
J. P. Holmes, L. C. Benavides, J. D. Gates, M. G. Carmichael, M. T. Hueman, E. A. Mittendorf, J. L. Murray, A. Amin, D. Craig, E. von Hofe, et al. (2008)
J. Clin. Oncol. 26, 3426-3433
   Abstract »    Full Text »    PDF »
Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties.
A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis (2008)
J. Immunol. 181, 146-154
   Abstract »    Full Text »    PDF »
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
D. Zhang, A. Pal, W. G. Bornmann, F. Yamasaki, F. J. Esteva, G. N. Hortobagyi, C. Bartholomeusz, and N. T. Ueno (2008)
Mol. Cancer Ther. 7, 1846-1850
   Abstract »    Full Text »    PDF »
Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth.
X.-C. Qiu, Y.-M. Xu, F. Wang, Q.-Y. Fan, L.-F. Wang, B.-A. Ma, L.-T. Jia, J. Zhao, Y.-L. Meng, L.-B. Yao, et al. (2008)
Mol. Cancer Ther. 7, 1890-1899
   Abstract »    Full Text »    PDF »
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer.
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al. (2008)
J. Clin. Oncol. 26, 2999-3005
   Abstract »    Full Text »    PDF »
HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective.
S. Kulkarni and D. G. Hicks (2008)
Ann. Surg. Oncol. 15, 1677-1688
   Abstract »    Full Text »    PDF »
Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
I. J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray (2008)
Oncologist 13, 620-630
   Abstract »    Full Text »    PDF »
Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPAR{beta}/{delta} to RAR.
T. T. Schug, D. C. Berry, I. A. Toshkov, L. Cheng, A. Y. Nikitin, and N. Noy (2008)
PNAS 105, 7546-7551
   Abstract »    Full Text »    PDF »
Signaling through ShcA Is Required for Transforming Growth Factor {beta}- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion.
J. J. Northey, J. Chmielecki, E. Ngan, C. Russo, M. G. Annis, W. J. Muller, and P. M. Siegel (2008)
Mol. Cell. Biol. 28, 3162-3176
   Abstract »    Full Text »    PDF »
The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity.
A. L. Willis, N. L. Tran, J. M. Chatigny, N. Charlton, H. Vu, S. A.N. Brown, M. A. Black, W. S. McDonough, S. P. Fortin, J. R. Niska, et al. (2008)
Mol. Cancer Res. 6, 725-734
   Abstract »    Full Text »    PDF »
t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways.
X. Meng, S. F. Shoemaker, S. O. McGee, and M. M. Ip (2008)
Carcinogenesis 29, 1013-1021
   Abstract »    Full Text »    PDF »
Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer.
A. Jimeno, A. C. Tan, J. Coffa, N.V. Rajeshkumar, P. Kulesza, B. Rubio-Viqueira, J. Wheelhouse, B. Diosdado, W. A. Messersmith, C. Iacobuzio-Donahue, et al. (2008)
Cancer Res. 68, 2841-2849
   Abstract »    Full Text »    PDF »
Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis.
N. Dourdin, B. Schade, R. Lesurf, M. Hallett, R. J. Munn, R. D. Cardiff, and W. J. Muller (2008)
Cancer Res. 68, 2122-2131
   Abstract »    Full Text »    PDF »
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance.
G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff (2008)
Endocr. Rev. 29, 217-233
   Abstract »    Full Text »    PDF »
Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
K.-K. Kim, J. J. Lee, Y. Yang, K.-H. You, and J.-H. Lee (2008)
Carcinogenesis 29, 704-712
   Abstract »    Full Text »    PDF »
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
R. A. Lubet, E. Szabo, K. Christov, A. M. Bode, M. E. Ericson, V. E. Steele, M. M. Juliana, and C. J. Grubbs (2008)
Mol. Cancer Ther. 7, 972-979
   Abstract »    Full Text »    PDF »
Trastuzumab plus Paclitaxel or Docetaxel in HER-2-Negative/HER-2 ECD-Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer.
A. Ardavanis, P. Kountourakis, F. Kyriakou, S. Malliou, I. Mantzaris, A. Garoufali, I. Yiotis, A. Scorilas, N. Baziotis, and G. Rigatos (2008)
Oncologist 13, 361-369
   Abstract »    Full Text »    PDF »
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group.
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard (2008)
J. Clin. Oncol. 26, 1419-1426
   Abstract »    Full Text »    PDF »
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial.
E. A. Perez, V. J. Suman, N. E. Davidson, G. W. Sledge, P. A. Kaufman, C. A. Hudis, S. Martino, J. R. Gralow, S. R. Dakhil, J. N. Ingle, et al. (2008)
J. Clin. Oncol. 26, 1231-1238
   Abstract »    Full Text »    PDF »
Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.
P. M Wilson, A. M Booth, A. Eastwood, and I. S Watt (2008)
J R Soc Med 101, 125-132
   Abstract »    Full Text »    PDF »
Geldanamycin-Induced Down-Regulation of ErbB2 from the Plasma Membrane Is Clathrin Dependent but Proteasomal Activity Independent.
N. M. Pedersen, I. H. Madshus, C. Haslekas, and E. Stang (2008)
Mol. Cancer Res. 6, 491-500
   Abstract »    Full Text »    PDF »
GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
T. Bai and S.-W. Luoh (2008)
Carcinogenesis 29, 473-479
   Abstract »    Full Text »    PDF »
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh (2008)
Ann. Onc. 19, 487-495
   Abstract »    Full Text »    PDF »
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
C L Hyun, H E Lee, K S Kim, S-W Kim, J H Kim, G Choe, and S Y Park (2008)
J. Clin. Pathol. 61, 317-321
   Abstract »    Full Text »    PDF »
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting.
D. A. Eberhard, G. Giaccone, and B. E. Johnson (2008)
J. Clin. Oncol. 26, 983-994
   Abstract »    Full Text »    PDF »
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options.
A. Ocana and A. Pandiella (2008)
Clin. Cancer Res. 14, 961-970
   Abstract »    Full Text »    PDF »
Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains.
P. A. Barthelemy, H. Raab, B. A. Appleton, C. J. Bond, P. Wu, C. Wiesmann, and S. S. Sidhu (2008)
J. Biol. Chem. 283, 3639-3654
   Abstract »    Full Text »    PDF »
Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers.
J. Wang, R. Day, Y. Dong, S. J. Weintraub, and L. Michel (2008)
Mol. Cancer Ther. 7, 280-285
   Abstract »    Full Text »    PDF »
Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
G. E. Peoples, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, A. Amin, S. Khoo, Z. A. Dehqanzada, J. M. Gurney, M. M. Woll, G. B. Ryan, et al. (2008)
Clin. Cancer Res. 14, 797-803
   Abstract »    Full Text »    PDF »
Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression.
Y. Wang, D. M. Ikeda, B. Narasimhan, T. A. Longacre, R. J. Bleicher, S. Pal, R. J. Jackman, and S. S. Jeffrey (2008)
Radiology 246, 367-375
   Abstract »    Full Text »    PDF »
A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2.
K. Sidera, M. Gaitanou, D. Stellas, R. Matsas, and E. Patsavoudi (2008)
J. Biol. Chem. 283, 2031-2041
   Abstract »    Full Text »    PDF »
Mutational Activation of ErbB2 Reveals a New Protein Kinase Autoinhibition Mechanism.
Y.-X. Fan, L. Wong, J. Ding, N. A. Spiridonov, R. C. Johnson, and G. R. Johnson (2008)
J. Biol. Chem. 283, 1588-1596
   Abstract »    Full Text »    PDF »
HER2 as a Predictive Marker: Why Bother Testing?.
A. C. Wolff, S. Paik, and M. F. Press (2008)
ASCO Educational Book 2008, 25-28
   Abstract »    Full Text »    PDF »
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff (2008)
J. Clin. Pathol. 61, 89-94
   Abstract »    Full Text »    PDF »
An EGR2/CITED1 Transcription Factor Complex and the 14-3-3{sigma} Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer.
R. L. Dillon, S. T. Brown, C. Ling, T. Shioda, and W. J. Muller (2007)
Mol. Cell. Biol. 27, 8648-8657
   Abstract »    Full Text »    PDF »
RIN1 Is a Breast Tumor Suppressor Gene.
M. Milstein, C. K. Mooser, H. Hu, M. Fejzo, D. Slamon, L. Goodglick, S. Dry, and J. Colicelli (2007)
Cancer Res. 67, 11510-11516
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)